Indivumed at ESMO Congress 2026
October 23 – 27, 2026 | IFEMA Madrid, Spain
ESMO 2026From clinical questions to individual tumor biology
ESMO brings the oncology community together to explore the future of cancer care. Many of the questions discussed there, such as who responds to a treatment and why, start with the biology of the tumor.
That is where we begin. At Indivumed, we build oncology programs on tumor biology preserved from the point of collection and define patient, target, and modality together.
Our CEO Prof. Dr. Hartmut Juhl and our VP Clinical Network, Nina Gabelia, MD, MPH, will be at IFEMA Madrid throughout the congress. Let’s connect in Madrid!
Cancer care is shaped by what we understand about the tumor.
Poster presentation co-authored by IndivumedPaired tumor-normal analysis in lung cancer
A poster co-authored by our CEO Prof. Dr. Hartmut Juhl and Nina Gabelia, MD, MPH, asks what changes in lung tissue as it becomes tumor, and what a paired analysis can show that tumor-only data cannot.
- Title: Smoking-associated gene expression changes in paired tumor and normal lung specimens from resected NSCLC: A TITANIA subset analysis
- Poster: 4393P | Friday, October 23, 2026 | 15:15-16:00 | Translational research and biomarkers
- Led by: National Cancer Center Hospital East, Kashiwa, Japan
- Takeaway: In this exploratory analysis of 23 NSCLC tumors, comparing tumor with matched normal tissue revealed gene expression patterns that tumor-only analysis did not show